DOCSLIB.ORG

Table 1 Gene Expression Fold Change* HIV∆2GFP HIV∆3GFP Gene Symbol Gene Title: a B C a B C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table 1 Gene Expression Fold Change* HIV∆2GFP HIV∆3GFP Gene Symbol Gene Title: a B C a B C Table 1 Gene Expression Fold Change* HIV∆2GFP HIV∆3GFP Gene Symbol Gene Title: A B C A B C . Apoptosis and Cell Cycle BCAR3 breast cancer anti-estrogen resistance 3 3.9 2.0 2.3 4.8 1.6 3.0 BCL2A1 BCL2-related protein A1 4.1 5.1 3.5 3.4 3.5 2.0 CYP4V2 cytochrome P450, family 4, subfamily V, polypeptide 2 2.4 1.4 2.5 2.0 1.6 2.4 DDIT4 DNA-damage-inducible transcript 4 2.5 2.5 1.8 2.8 2.8 1.9 EGFL6 EGF-like-domain, multiple 6 2.1 3.0 4.0 1.9 1.8 2.3 F2R coagulation factor II (thrombin) receptor 3.6 2.3 3.4 1.7 1.2 2.1 FOXO3A Forkhead box O3A 1.7 4.3 2.3 1.1 3.7 2.2 GZMB granzyme B (cytotoxic T-lymphocyte-associated serine esterase 1) 3.7 2.7 1.4 4.2 2.7 1.4 GZMH granzyme H (cathepsin G-like 2, protein h-CCPX) 2.9 3.7 2.2 3.3 2.8 2.6 IER3 immediate early response 3 1.5 3.3 5.2 1.8 3.9 3.6 MDM2 Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) 1.6 2.2 2.4 2.1 1.7 1.9 NCKAP1 NCK-associated protein 1 3.1 2.4 1.6 1.7 1.8 1.0 PHLDA1 pleckstrin homology-like domain, family A, member 1 2.3 2.1 1.7 3.1 3.6 2.6 PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 2.1 1.8 3.4 2.0 2.1 3.2 PPAP2A phosphatidic acid phosphatase type 2A 3.3 1.7 2.7 2.7 2.1 2.5 RAP1A RAP1A, member of RAS oncogene family 4.9 6.5 4.5 4.2 4.7 4.5 RNF130 ring finger protein 130 10.4 3.4 2.5 7.0 2.4 2.7 SQSTM1 Sequestosome 1 1.0 3.5 1.9 1.3 2.7 2.2 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 1.1 2.2 2.5 1.7 2.8 3.0 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 1.3 3.0 1.9 1.6 2.2 1.9 TNFRSF10A tumor necrosis factor receptor superfamily, member 10a 2.1 1.6 1.8 1.6 1.2 1.6 TNFRSF10B tumor necrosis factor receptor superfamily, member 10b 2.0 4.2 5.1 2.6 2.4 1.8 TNFRSF18 tumor necrosis factor receptor superfamily, member 18 2.0 2.8 2.2 2.7 2.0 1.9 TRAF4 TNF receptor-associated factor 4 2.2 1.8 1.9 2.5 2.3 1.9 Cell Adhesion BTBD9 BTB (POZ) domain containing 9 2.3 1.6 2.5 2.5 1.4 1.8 CALD1 caldesmon 1 3.5 3.9 3.2 3.6 8.7 4.6 CCL3 chemokine (C-C motif) ligand 3 1.2 4.6 2.4 7.1 14.6 4.2 CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2 5.0 2.7 2.0 5.1 1.9 2.2 CMTM2 CKLF-like MARVEL transmembrane domain containing 2 1.5 1.7 3.9 2.0 2.5 4.1 INPP5A inositol polyphosphate-5-phosphatase, 40kDa 1.9 2.2 2.1 1.6 2.2 1.8 PECAM1 Platelet/endothelial cell adhesion molecule (CD31 antigen) 3.1 2.3 3.7 2.2 1.1 2.0 Cell Growth and Development ATN1 Atrophin 1 1.8 1.6 1.8 2.3 2.9 1.8 CRIM1 cysteine rich transmembrane BMP regulator 1 (chordin-like) 2.3 2.0 1.5 1.8 1.7 1.3 CSF1 colony stimulating factor 1 (macrophage) 2.2 2.0 1.7 2.5 3.4 2.1 EPAS1 endothelial PAS domain protein 1 2.4 4.3 3.1 2.6 3.1 2.8 FMNL3 Formin-like 3 3.6 1.9 2.7 2.0 1.1 3.2 IL12RB2 Interleukin 12 receptor, beta 2 2.0 1.3 2.3 3.0 1.6 3.1 VAT1 vesicle amine transport protein 1 homolog (T californica) 3.4 1.7 2.0 2.8 1.7 0.8 Chromatin Remodeling CTAGE5 CTAGE family, member 5 2.4 1.2 2.0 2.4 1.6 2.0 RBM6 RNA binding motif protein 6 2.1 1.5 2.6 1.9 1.2 1.6 SATB1 Special AT-rich sequence binding protein 1 2.3 2.3 1.8 1.7 1.4 1.6 SIRT2 Sirtuin (silent mating type information regulation 2 homolog) 2 (S. cerevisiae) 1.7 3.2 3.1 1.5 2.5 2.2 Immune Response ALOX5 arachidonate 5-lipoxygenase 4.5 1.7 4.7 1.6 0.8 3.2 BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51) 11.9 26.6 15.4 3.9 5.7 3.5 C3AR1 complement component 3a receptor 1 2.4 2.2 1.7 1.7 2.1 1.9 CCL5 chemokine (C-C motif) ligand 5 2.2 2.3 1.7 2.2 2.3 1.5 CCR1 chemokine (C-C motif) receptor 1 2.1 1.2 2.0 2.5 1.8 2.5 CD69 CD69 molecule 2.8 2.6 3.0 2.6 2.5 3.1 CD96 CD96 molecule 2.3 2.0 2.1 2.1 1.5 1.9 CYSLTR1 cysteinyl leukotriene receptor 1 6.1 3.5 3.2 2.5 1.4 2.3 IFI44L interferon-induced protein 44-like 2.4 4.9 7.4 1.4 2.0 1.7 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 2.1 5.7 3.4 1.8 1.7 2.3 IL13 interleukin 13 1.4 1.9 1.6 5.6 2.6 3.2 IL17A interleukin 17A 2.6 9.2 2.5 3.7 14.2 3.3 IL18R1 interleukin 18 receptor 1 3.2 2.8 4.1 2.8 2.4 2.9 IL18RAP interleukin 18 receptor accessory protein 7.0 6.2 6.3 4.3 2.1 2.1 IL1RN interleukin 1 receptor antagonist 3.2 3.0 4.8 3.7 7.2 3.6 IRAK2 interleukin-1 receptor-associated kinase 2 1.7 3.6 2.9 1.6 2.5 2.2 *relative to eGFP control Table 1 Gene Expression Fold Change* HIV∆2GFP HIV∆3GFP Gene Symbol Gene Title: A B C A B C . OASL 2'-5'-oligoadenylate synthetase-like 1.8 2.8 2.2 2.1 3.1 2.2 PROCR Protein C receptor, endothelial (EPCR) 4.9 2.7 1.9 2.8 2.0 2.1 TNFSF4 tumor necrosis factor (ligand) superfamily, member 4 4.4 7.6 4.7 3.3 2.0 2.1 Metabolism CTH cystathionase (cystathionine gamma-lyase) 2.1 1.8 2.1 2.2 2.5 1.8 DHCR7 7-dehydrocholesterol reductase 2.1 2.0 1.7 1.4 1.9 1.6 DHRS3 dehydrogenase/reductase (SDR family) member 3 1.7 8.9 11.2 1.9 2.6 7.6 HBS1L HBS1-like (S. cerevisiae) 2.3 1.7 2.4 1.8 1.1 2.1 MAN1C1 mannosidase, alpha, class 1C, member 1 2.3 4.2 3.6 2.5 1.4 3.0 MOCOS molybdenum cofactor sulfurase 2.8 2.1 1.5 2.7 2.5 1.5 MTHFD1 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 4.2 3.4 3.0 2.4 4.0 3.3 P4HA2 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase) 2.7 3.9 4.4 2.8 2.6 4.3 TMEM23 Transmembrane protein 23 10.4 2.9 2.4 8.9 1.8 2.1 TUBB2A tubulin, beta 2A 1.7 3.3 1.9 2.4 3.3 1.9 Protein Modification CDKL3 cyclin-dependent kinase-like 3 2.5 2.3 1.5 1.6 1.3 1.6 CPM Carboxypeptidase M 1.5 3.1 3.7 1.5 2.1 1.7 CTSL cathepsin L 2.8 3.6 1.9 2.1 2.1 1.2 DNAJB2 DnaJ (Hsp40) homolog, subfamily B, member 2 1.9 2.2 2.3 1.6 2.0 2.0 MGAT5 Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase 6.2 14.0 1.4 3.0 8.7 2.2 PRKCE protein kinase C, epsilon 2.8 3.5 3.3 1.6 1.9 3.3 PTPN2 Protein tyrosine phosphatase, non-receptor type 2 1.4 2.3 2.2 1.4 1.6 1.8 RNF144 ring finger protein 144 2.7 2.6 3.6 1.2 1.7 3.7 YES1 V-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 2.0 2.8 3.3 1.8 1.4 2.3 Signal Transduction ANK3 ankyrin 3, node of Ranvier (ankyrin G) 2.0 4.0 3.4 1.4 2.2 1.9 DUSP8 dual specificity phosphatase 8 1.7 3.3 2.2 1.5 4.4 2.1 HBEGF heparin-binding EGF-like growth factor 2.7 2.6 2.0 2.0 2.7 2.0 ITPR1 Inositol 1,4,5-triphosphate receptor, type 1 6.6 1.5 2.0 4.8 1.7 1.9 NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 1.8 2.1 2.5 2.0 2.3 2.9 P2RY14 purinergic receptor P2Y, G-protein coupled, 14 2.6 9.4 4.4 2.6 4.7 3.9 PDE3B Phosphodiesterase 3B, cGMP-inhibited 2.1 2.3 2.6 2.2 1.8 3.1 PDE4A phosphodiesterase 4A, cAMP-specific 2.4 2.0 2.1 1.8 1.6 1.6 PDE4D Phosphodiesterase 4D, cAMP-specific 2.0 1.6 2.0 2.1 1.6 2.3 PIK3AP1 phosphoinositide-3-kinase adaptor protein 1 2.1 1.4 2.1 2.5 1.2 2.3 PMCH pro-melanin-concentrating hormone 2.2 5.1 8.4 2.5 3.3 3.2 PPAP2A phosphatidic acid phosphatase type 2A 3.3 1.7 2.7 2.7 2.1 2.5 RASGRF2 Ras protein-specific guanine nucleotide-releasing factor 2 4.5 2.9 2.1 2.2 2.5 2.8 SOS2 Son of sevenless homolog 2 (Drosophila) 1.7 3.0 2.9 1.4 1.8 1.9 SYTL3 synaptotagmin-like 3 1.5 3.5 2.7 1.4 2.7 2.0 TFG TRK-fused gene 3.2 0.4 1.6 2.8 1.5 2.7 TIAM1 T-cell lymphoma invasion and metastasis 1 3.6 2.2 2.0 2.1 1.4 1.6 Transcription ATF3 activating transcription factor 3 2.5 3.5 2.9 2.5 1.9 2.4 BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51) 11.9 26.6 15.4 3.9 5.7 3.5 BCORL2 BCL6 co-repressor-like 2 2.5 1.9 2.1 2.1 0.6 2.7 CREM cAMP responsive element modulator 2.0 2.7 2.5 2.6 3.2 2.6 EGR1 early growth response 1 3.9 3.3 1.8 4.9 4.6 2.0 ETV6 Ets variant gene 6 (TEL oncogene) 2.0 2.3 3.1 1.4 1.6 2.9 FOSL2 FOS-like antigen 2 2.0 1.7 2.0 1.7 2.3 2.0 FOXP1 Forkhead box P1 4.3 2.3 3.2 2.8 1.2 2.7 HDAC4 histone deacetylase 4 1.9 2.1 2.4 1.2 1.6 1.9 HLF hepatic leukemia factor 0.8 2.7 1.9 3.3 4.7 3.0 IRF8 interferon regulatory factor 8 2.5 2.1 2.0 1.8 1.6 1.9 JUN v-jun sarcoma virus 17 oncogene homolog (avian) 2.5 2.3 2.7 1.9 2.1 1.9 MAML3 mastermind-like 3 (Drosophila) 1.7 1.8 5.6 2.1 3.6 4.3 NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 2.2 1.6 2.0 2.2 1.3 3.0 RUNX1 runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) 1.3 2.9 2.6 1.7 2.4 2.4 SMAD1 SMAD, mothers against DPP homolog 1 (Drosophila) 1.0 6.8 2.8 0.9 1.8 1.6 STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor) 1.5 1.8 2.5 1.7 2.2 2.1 TCERG1 Transcription elongation regulator 1 2.4 1.0 1.6 2.9 3.3 1.9 TWIST1 twist homolog 1 (acrocephalosyndactyly 3; Saethre-Chotzen syndrome) 4.6 2.4 2.2 5.6 1.6 1.7 ZBTB10 Zinc finger and BTB domain containing 10 2.2 3.6 2.4 1.5 1.6 1.6 *relative to eGFP control Table 1 Gene Expression Fold Change* HIV∆2GFP HIV∆3GFP Gene Symbol Gene Title: A B C A B C .
Load more

Recommended publications
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]
  • Detection of Genetic Variations of Five MMAF-Related Genes and Their
    Detection of genetic variations of ve MMAF-related genes and their associations with litter size in goat Zhen Wang Northwest Agriculture and Forestry University Yun Pan Northwest Agriculture and Forestry University Libang He Northwest Agriculture and Forestry University Hong Chen Northwest Agriculture and Forestry University Chuanying Pan Northwest Agriculture and Forestry University Lei Qu Yulin University Xiaoyue Song Yulin University Xianyong Lan ( [email protected] ) https://orcid.org/0000-0003-2254-5805 Research article Keywords: goats; insertion/deletion (indel); MMAF; DNAH1; litter sizes; correlation analysis Posted Date: September 12th, 2019 DOI: https://doi.org/10.21203/rs.2.14419/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/13 Abstract Background: Multiple morphological abnormalities of the sperm agella (MMAF) makes an assignable contribution to male infertility, including QRICH2 , CFAP43 , CFAP44 , CFAP69 , CCDC39 , AKAP4 and DNAH1 gene. This work studied 28 putative indel mutations of MMAF related genes including QRICH2 , CFAP69 , CFAP43 , CCDC39 and DNAH1 gene and their correlation with the rst-born litter sizes of 769 Shaanbei white cashmere (SBWC) goats. Results: Electrophoresis and DNA sequencing analysis showed the 11-bp indel within QRICH2 ( QRICH2 -P4), the three indel variations in CFAP69 ( CFAP69 -P4, CFAP69 - P6 and CFAP69 -P7) and the 27-bp indel of DNAH1 ( DNAH1 -P1) were found to be polymorphic. The 27- bp indel variation within DNAH1 was not in consistent with HWE and the other four indel of QRICH2 and CFAP69 were in consistent with HWE. The linkage disequilibrium (LD) analysis showed the 8-bp indel ( CFAP69 -P4) and the 6-bp indel ( CFAP69- P6) within CFAP69 were in complete LD with each other (D'=0.99, r 2 =1.00).
    [Show full text]
  • Article Reference
    Article Comprehensive evaluation of coding region point mutations in microsatellite‐unstable colorectal cancer KONDELIN, Johanna, et al. Reference KONDELIN, Johanna, et al. Comprehensive evaluation of coding region point mutations in microsatellite‐unstable colorectal cancer. EMBO Molecular Medicine, 2018, vol. 10, no. 9, p. e8552 PMID : 30108113 DOI : 10.15252/emmm.201708552 Available at: http://archive-ouverte.unige.ch/unige:120174 Disclaimer: layout of this document may differ from the published version. 1 / 1 Published online: August 14, 2018 Report Comprehensive evaluation of coding region point mutations in microsatellite-unstable colorectal cancer Johanna Kondelin1,2, Kari Salokas3,4, Lilli Saarinen2, Kristian Ovaska2, Heli Rauanheimo1,2, Roosa-Maria Plaketti1,2, Jiri Hamberg1,2, Xiaonan Liu3,4 , Leena Yadav3,4, Alexandra E Gylfe1,2, Tatiana Cajuso1,2, Ulrika A Hänninen1,2, Kimmo Palin1,2, Heikki Ristolainen1,2, Riku Katainen1,2, Eevi Kaasinen1,2, Tomas Tanskanen1,2, Mervi Aavikko1,2, Minna Taipale5, Jussi Taipale1,2,6,7 , Laura Renkonen-Sinisalo8, Anna Lepistö8, Selja Koskensalo9, Jan Böhm10, Jukka-Pekka Mecklin11,12, Halit Ongen13,14,15, Emmanouil T Dermitzakis13,14,15, Outi Kilpivaara1,2, Pia Vahteristo1,2, Mikko Turunen2, Sampsa Hautaniemi2, Sari Tuupanen1,2, Auli Karhu1,2, Niko Välimäki1,2, Markku Varjosalo3,4, Esa Pitkänen1,2 & Lauri A Aaltonen1,2,* Abstract not been linked to CRC before. Two genes, SMARCB1 and STK38L, were also functionally scrutinized, providing evidence of Microsatellite instability (MSI) leads to accumulation of an a tumorigenic role, for SMARCB1 mutations in particular. excessive number of mutations in the genome, mostly small insertions and deletions. MSI colorectal cancers (CRCs), however, Keywords cancer genetics; colorectal cancer; microsatellite instability also contain more point mutations than microsatellite-stable Subject Categories Cancer; Chromatin, Epigenetics, Genomics & Functional (MSS) tumors, yet they have not been as comprehensively stud- Genomics; Systems Medicine ied.
    [Show full text]
  • Insights Into MYC Biology Through Investigation of Synthetic Lethal Interactions with MYC Deregulation
    Insights into MYC biology through investigation of synthetic lethal interactions with MYC deregulation Mai Sato Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Mai Sato All Rights Reserved ABSTRACT Insights into MYC biology through investigation of synthetic lethal interactions with MYC deregulation Mai Sato MYC (or c-myc) is a bona fide “cancer driver” oncogene that is deregulated in up to 70% of human tumors. In addition to its well-characterized role as a transcription factor that can directly promote tumorigenic growth and proliferation, MYC has transcription-independent functions in vital cellular processes including DNA replication and protein synthesis, contributing to its complex biology. MYC expression, activity, and stability are highly regulated through multiple mechanisms. MYC deregulation triggers genome instability and oncogene-induced DNA replication stress, which are thought to be critical in promoting cancer via mechanisms that are still unclear. Because regulated MYC activity is essential for normal cell viability and MYC is a difficult protein to target pharmacologically, targeting genes or pathways that are essential to survive MYC deregulation offer an attractive alternative as a means to combat tumor cells with MYC deregulation. To this end, we conducted a genome-wide synthetic lethal shRNA screen in MCF10A breast epithelial cells stably expressing an inducible MYCER transgene. We identified and validated FBXW7 as a high-confidence synthetic lethal (MYC-SL) candidate gene. FBXW7 is a component of an E3 ubiquitin ligase complex that degrades MYC. FBXW7 knockdown in MCF10A cells selectively induced cell death in MYC-deregulated cells compared to control.
    [Show full text]
  • A Yeast Bifc-Seq Method for Genome-Wide Interactome Mapping
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.16.154146; this version posted June 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 A yeast BiFC-seq method for genome-wide interactome mapping 2 3 Limin Shang1,a, Yuehui Zhang1,b, Yuchen Liu1,c, Chaozhi Jin1,d, Yanzhi Yuan1,e, 4 Chunyan Tian1,f, Ming Ni2,g, Xiaochen Bo2,h, Li Zhang3,i, Dong Li1,j, Fuchu He1,*,k & 5 Jian Wang1,*,l 6 1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National 7 Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, 8 China; 2Department of Biotechnology, Beijing Institute of Radiation Medicine, 9 Beijing 100850, China; 3Department of Rehabilitation Medicine, Nan Lou; 10 Department of Key Laboratory of Wound Repair and Regeneration of PLA, College 11 of Life Sciences, Chinese PLA General Hospital, Beijing 100853, China; 12 Correspondence should be addressed to F.H. ([email protected]) and J.W. 13 ([email protected]). 14 * Corresponding authors. 15 E-mail：[email protected] (Fuchu He)，[email protected] (Jian Wang) 16 a ORCID: 0000-0002-6371-1956. 17 b ORCID: 0000-0001-5257-1671 18 c ORCID: 0000-0003-4691-4951 19 d ORCID: 0000-0002-1477-0255 20 e ORCID: 0000-0002-6576-8112 21 f ORCID: 0000-0003-1589-293X 22 g ORCID: 0000-0001-9465-2787 23 h ORCID: 0000-0003-3490-5812 24 i ORCID: 0000-0002-3477-8860 25 j ORCID: 0000-0002-8680-0468 26 k ORCID: 0000-0002-8571-2351 27 l ORCID: 0000-0002-8116-7691 28 Total word counts:4398 (from “Introduction” to “Conclusions”) 29 Total Keywords: 5 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.16.154146; this version posted June 17, 2020.
    [Show full text]
  • Characterization and Expression Profile of CMTM3/CKLFSF3
    Journal of Biochemistry and Molecular Biology, Vol. 39, No. 5, September 2006, pp. 537-545 Characterization and Expression Profile of CMTM3/CKLFSF3 Ji Zhong, Yu Wang, Xiaoyan Qiu, Xiaoning Mo, Yanan Liu, Ting Li, Quansheng Song, Dalong Ma and Wenling Han* Peking University Center for Human Disease Genomics, 38 Xueyuan Road, Beijing 100083, China Received 22 February 2006, Accepted 10 May 2006 CMTM/CKLFSF is a novel family of proteins linking Introduction chemokines and TM4SF. In humans, these proteins are encoded by nine genes, CKLF and CMTM1-8/CKLFSF1-8. CKLFSF is a novel family of proteins linking chemokines and Here we report the characteristics and expression profile Transmembrane 4 Super Family (TM4SF), which are encoded of CMTM3/CKLFSF3. Human CMTM3/CKLFSF3 has a by nine genes, CKLF and CKLFSF1-8, in humans. CKLF, high sequence identity among various species and similar CKLFSF1, and CKLFSF2 are active during evolution, and characteristics as its mouse and rat homologues. Established CKLFSF2 has two orthologues in rat and mouse designated by results both of RT-PCR and Quantitative Real-time Cklfsf2a and Cklfsf2b. CKLFSF3-8 are evolutionarily conserved. PCR, the gene is highly transcribed in testis, leukocytes CKLFSF members form two gene clusters: CKLF and and spleen. For further verification, we generated a CKLFSF1-4 at chromosome 16q22.1, and CKLFSF6-8 at polyclonal antibody against human CMTM3/CKLFSF3 chromosome 3p23. Most CKLFSFs have different spliced and found that the protein is highly expressed in the testis forms, and the protein product of at least one spliced form of and some cells of PBMCs.
    [Show full text]
  • RNA-Seq Transcriptome Analysis for the Study of Prostate Cancer Development and Evolution
    MASTER THESIS RNA-Seq Transcriptome Analysis for the Study of Prostate Cancer Development and Evolution Esther Sauras Colón Tutors: María Jesús Álvarez Cubero, Eduardo Andrés León September 2019 MASTER IN TRANSLATIONAL RESEARCH AND PERSONALIZED MEDICINE Master Thesis RNA-Seq Transcriptome Analysis for the Study of Prostate Cancer Development and Evolution Esther Sauras Colón 1*, María Jesús Álvarez Cubero 2,3* and Eduardo Andrés León 4* 1 Master in Translational Research and Personalized Medicine. Faculty of Medicine, University of Granada. Granada, Spain. 2 GENYO. Centre for Genomics and Oncological Research. Pfizer / University of Granada / Andalusian Regional Government. Granada, Spain. 3 Department of Biochemistry and Molecular Biology III. Faculty of Medicine, University of Granada. Granada, Spain. 4 Bioinformatics Unit, Institute of Parasitology and Biomedicine “López-Neyra” (IPBLN). Spanish National Research Council (CSIC). Granada, Spain. * Correspondence: Esther Sauras Colón: [email protected]. María Jesús Álvarez Cubero: [email protected]. Eduardo Andrés León: [email protected]. September 2019 Abstract: Prostate cancer (PCa) is one of the most common cancers worldwide. Even though prostate specific antigen (PSA) test is the non-invasive routine blood test for the detection of asymptomatic disease, it can result in problems of diagnostic accuracy and overdiagnosis. Thus, it is necessary to continue investigating new efficient biomarkers for the prevention, diagnosis and prognosis of PCa. Here, we analyse the transcriptome of seven individuals by the use of next-generation sequencing (NGS) technique to identify differentially expressed genes, which can help to better understand PCa aggressiveness. Present analysis show that there are two upregulated genes in PCa regarding to controls: HP (Haptoglobin) and HLA-G (Human Leukocyte Antigen-G).
    [Show full text]
  • Human Social Genomics in the Multi-Ethnic Study of Atherosclerosis
    Getting “Under the Skin”: Human Social Genomics in the Multi-Ethnic Study of Atherosclerosis by Kristen Monét Brown A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Epidemiological Science) in the University of Michigan 2017 Doctoral Committee: Professor Ana V. Diez-Roux, Co-Chair, Drexel University Professor Sharon R. Kardia, Co-Chair Professor Bhramar Mukherjee Assistant Professor Belinda Needham Assistant Professor Jennifer A. Smith © Kristen Monét Brown, 2017 [email protected] ORCID iD: 0000-0002-9955-0568 Dedication I dedicate this dissertation to my grandmother, Gertrude Delores Hampton. Nanny, no one wanted to see me become “Dr. Brown” more than you. I know that you are standing over the bannister of heaven smiling and beaming with pride. I love you more than my words could ever fully express. ii Acknowledgements First, I give honor to God, who is the head of my life. Truly, without Him, none of this would be possible. Countless times throughout this doctoral journey I have relied my favorite scripture, “And we know that all things work together for good, to them that love God, to them who are called according to His purpose (Romans 8:28).” Secondly, I acknowledge my parents, James and Marilyn Brown. From an early age, you two instilled in me the value of education and have been my biggest cheerleaders throughout my entire life. I thank you for your unconditional love, encouragement, sacrifices, and support. I would not be here today without you. I truly thank God that out of the all of the people in the world that He could have chosen to be my parents, that He chose the two of you.
    [Show full text]
  • A Genome-Wide Association Study of Equine Metabolic Syndrome And
    A GENOME-WIDE ASSOCIATION STUDY OF EQUINE METABOLIC SYNDROME AND PITUITARY PARS INTERMEDIA DYSFUNCTION A Thesis Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Master of Science by Cassandra Lois Streeter January 2012 © 2012 Cassandra Lois Streeter ABSTRACT Laminitis remains a poorly understood form of lameness in the horse despite being heavily researched. Endocrinopathic laminitis is an insidious form of laminitis that often results from insulin resistance (an indicator of Equine Metabolic Syndrome or EMS) or equine pituitary pars intermedia dysfunction (PPID). Both conditions occur in older horses with PPID having a later age of onset than EMS and horses are often characterized as having a “cresty” neck. EMS horses have persistent hyperinsulinemia while horses affected by PPID have elevated ACTH levels. Though no specific genetic predispositions have been identified for EMS or PPID, ponies are frequently observed to have both conditions. The objective of this study was to conduct a genome-wide association to identify candidate genes that may predispose individuals to EMS, PPID or both. A total of 65 horses, at least ten years old and of full or majority Arabian descent were divided into four categories based on previous endocrinology testing. Horses with ACTH levels greater than 70 pg/mL and insulin levels less than 40 uIU/mL were designated “PPID” while horses with insulin levels > 70 uIU/mL and ACTH levels less than 40 pg/mL were designated “EMS”. Horses with ACTH and insulin levels < 40 pg/mL or uIU/mL, respectively, were considered “Normal” and those with both levels > 70 were grouped into the fourth category termed “Both”.
    [Show full text]
  • Roles in Cancer Biological Processes and Potential Clinical Value
    Cancer Biol Med 2020. doi: 10.20892/j.issn.2095-3941.2020.0032 REVIEW CMTM family proteins 1–8: roles in cancer biological processes and potential clinical value Jie Wu*, Lan Li*, Siyi Wu, Bin Xu Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China ABSTRACT The CKLF-like MARVEL transmembrane domain containing (CMTM) family of genes comprises CKLF and CMTM1–8 (previously called chemokine-like factor superfamily 1–8, CKLFSF1–8). The CMTM family proteins contain a structurally conserved MAL and related proteins for vesicle trafficking and membrane linking (MARVEL) domain. Dysregulated expression of multiple CMTM family members is a common feature in many human cancer types. CMTM proteins control critical biological processes in cancer development, including growth factor receptor activation and recycling, cell proliferation, apoptosis, metastasis, and immune evasion. Emerging in vivo and in vitro evidence indicates that the mechanisms of action of most CMTM proteins are complex and multifactorial. This review highlights new findings regarding the roles of CMTM1–8 in cancer, particularly in tumor growth, metastasis, and immune evasion. Additionally, the potential clinical value of CMTMs as novel drug targets or biomarkers is discussed. KEYWORDS CMTM family; cancer; cell cycle; EGFR; EMT; apoptosis; tumor immunity Introduction CMTM genes have been reported to be differentially expressed between tumor and normal tissue, thus suggesting Cancer is a highly heterogeneous group of diseases and one that CMTMs may actively regulate tumor development in of the leading causes of death worldwide. Each tumor type various cancer types4-10. The functions of CMTM family pro- exhibits distinct biological characteristics, clinical features, teins in tumor growth, metastasis, and antitumor immunity outcomes, and responses to therapies.
    [Show full text]
  • Comprehensive Analysis of the Prognosis for Chemokine-Like Factor MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma
    Comprehensive Analysis of the Prognosis for Chemokine-Like Factor MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma Dan Li Nanchang University Second Aliated Hospital Shenglan Huang Nanchang University Second Aliated Hospital Liying Sun Nanchang University Second Aliated Hospital Jianbing Wu ( [email protected] ) Nanchang University Second Aliated Hospital https://orcid.org/0000-0002-4576-7286 Research Article Keywords: CMTM, hepatocellular carcinoma, DNA methylation, prognosis, biomarkers Posted Date: August 3rd, 2021 DOI: https://doi.org/10.21203/rs.3.rs-749291/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/28 Abstract Background and Purpose: Chemokine-like factor (CKLF) MARVEL transmembrane domain-containing family (CMTMs), including chemokine-like factor (CKLF) and CMTM1 to CMTM8. All of these genes participate in tumor development and metastasis of hepatocellular carcinoma (HCC). However, prognosis values and the distinct roles of different CMTMs in HCC are still un-claried. Materials and Methods: To address this issue, the study explored the function of CMTM family members in the prognosis of HCC by TCGA dataset, UALCAN, Kaplan-Meier Plotter, MethSurv, TIMER2.0 databases. Results: The CKLF and CMTM1/3/4/7/8 mRNA expression was obviously elevated in HCC tissues, while CMTM2/5/6 was lowly expressed. Besides, the mRNA level of CMTMs was closely linked to cancer stage, node metastasis status and tumor grades in HCC patients. What’s more, the expression of CMTM2/5 was correlated with favorable overall survival (OS), while high expressions CKLF and CMTM1/7 were associated with poor OS. Simultaneously, low CKLF and CMTM1/4/7 expressions were signicantly relevant to better progression-free survival (PFS), while low CMTM5 expression was apparently concerned with worse PFS.
    [Show full text]
  • Cytokines Mapping for Tissue-Specific Expression, Eqtls and GWAS Traits
    www.nature.com/scientificreports OPEN Cytokines mapping for tissue‑specifc expression, eQTLs and GWAS traits Lyubov E. Salnikova1,2*, Maryam B. Khadzhieva1,2, Dmitry S. Kolobkov1,3,4, Alesya S. Gracheva1,2, Artem N. Kuzovlev2 & Serikbay K. Abilev1 Dysregulation in cytokine production has been linked to the pathogenesis of various immune‑ mediated traits, in which genetic variability contributes to the etiopathogenesis. GWA studies have identifed many genetic variants in or near cytokine genes, nonetheless, the translation of these fndings into knowledge of functional determinants of complex traits remains a fundamental challenge. In this study we aimed at collection, analysis and interpretation of data on cytokines focused on their tissue‑specifc expression, eQTLs and GWAS traits. Using GO annotations, we generated a list of 314 cytokines and analyzed them with the GTEx resource. Cytokines were highly tissue‑specifc, 82.3% of cytokines had Tau expression metrics ≥ 0.8. In total, 3077 associations for 1760 unique SNPs in or near 244 cytokines were mapped in the NHGRI‑EBI GWAS Catalog. According to the Experimental Factor Ontology resource, the largest numbers of disease associations were related to ‘Infammatory disease’, ‘Immune system disease’ and ‘Asthma’. The GTEx‑based analysis revealed that among GWAS SNPs, 1142 SNPs had eQTL efects and infuenced expression levels of 999 eGenes, among them 178 cytokines. Several types of enrichment analysis showed that it was cytokines expression variability that fundamentally contributed to the molecular origins of considered immune-mediated conditions. Cytokines are regulatory proteins and glycoproteins that are synthesized and secreted by immune system cells and other cell types. Tey regulate innate and acquired immunity, embryogenesis, hematopoiesis, infammation and regeneration processes, and proliferation.
    [Show full text]